Greenwich Lifesciences Inc GLSI
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-09-25 |
| Shares Out. | 14,680,000 |
| Website | greenwichlifesciences.com ↗ |
| Phone | 12034343290 |
| Employees | 13 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$3.9M |
| Free Cash Flow | -$12.5M |
| Total Assets | $8.9M |
| Total Liabilities | $5.8M |
| Equity | $3.1M |
About Greenwich Lifesciences Inc
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.
Greenwich Lifesciences Inc is a publicly traded company under the ticker symbol GLSI on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
8 analysts (2026-11-01)